Palvella Therapeutics Inc

At the Cantor Health conference Palvella outlined its focused strategy for rare skin diseases and vascular anomalies and confirmed submission of an NDA to the FDA for QTORIN (rapamycin) to treat microcystic lymphatic malformations (microLM). If granted a Priority Review, approval could occur in the first half of 2027; Phase III data showed improvement in 95% of patients. The company estimates at least 30,000 diagnosed US microLM patients and aims for an annual treatment price range of $100,000–$200,000, relies on extensive patent protection through at least 2038, and is pursuing additional programs for cutaneous venous malformations and DSAP. » Mais em de.investing.com

Palvella plans to file a rolling NDA for QTORIN Rapamycin for microcystic lymphatic malformations later this year and targets a potential US approval in the first half of 2027. The Phase III trial met its primary endpoint: 95% of patients showed improvement and 86% were rated as markedly/very markedly improved. The company has USD 251 million in cash, is preparing a commercial launch with a 40-person sales team and is targeting a treatment price of USD 100,000–200,000 per patient/year. In parallel, Palvella plans to expand QTORIN into additional indications (cutaneous venous malformations, angiokeratomas, DSAP) and to broaden the pipeline by year-end. » Mais em de.investing.com

Palvella reported a second-quarter loss of $1.52 per share (expectation -$1.16) and no revenue, but the stock rose 4.2% pre-market. The company has about $251 million in cash following a $230 million financing round and raised its expected 2026 cash burn to $85–95 million to expand sales, patient services and launch activities. Lead program QTORIN Rapamycin remains on track for an NDA submission in the second half of 2026 and potential FDA approval in the first half of 2027; Phase III data showed a 95% improvement in the primary endpoint. Management emphasizes financial flexibility and a focus on approval and commercialization preparations, but notes risks from regulation, execution and higher costs. » Mais em de.investing.com